US20070203185A1 - Therapeutical Composition Containing Dentritic Cells And Use Thereof - Google Patents
Therapeutical Composition Containing Dentritic Cells And Use Thereof Download PDFInfo
- Publication number
- US20070203185A1 US20070203185A1 US10/559,375 US55937504A US2007203185A1 US 20070203185 A1 US20070203185 A1 US 20070203185A1 US 55937504 A US55937504 A US 55937504A US 2007203185 A1 US2007203185 A1 US 2007203185A1
- Authority
- US
- United States
- Prior art keywords
- tlr
- agonist
- lymphocytes
- malp
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 34
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 138
- 238000000034 method Methods 0.000 claims abstract description 36
- 102000002689 Toll-like receptor Human genes 0.000 claims abstract description 30
- 108020000411 Toll-like receptor Proteins 0.000 claims abstract description 30
- 239000000556 agonist Substances 0.000 claims abstract description 24
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 24
- 239000000018 receptor agonist Substances 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 102000008228 Toll-like receptor 2 Human genes 0.000 claims abstract description 9
- 108010060888 Toll-like receptor 2 Proteins 0.000 claims abstract description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 48
- 108010074328 Interferon-gamma Proteins 0.000 claims description 34
- 239000011780 sodium chloride Substances 0.000 claims description 24
- 230000000172 allergic effect Effects 0.000 claims description 19
- 208000010668 atopic eczema Diseases 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 210000001616 monocyte Anatomy 0.000 claims description 11
- 230000035755 proliferation Effects 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 108010028921 Lipopeptides Proteins 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010017533 Fungal infection Diseases 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 6
- 208000030852 Parasitic disease Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000036281 parasite infection Effects 0.000 claims description 6
- DMWMUMWKGKGSNW-OPMCLZTFSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-4-amino-2-[[2-[[(2R)-2-amino-3-[(2R)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O)OC(=O)CCCCCCCCCCCCCCC DMWMUMWKGKGSNW-OPMCLZTFSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002538 fungal effect Effects 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 230000036210 malignancy Effects 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 241000202952 Mycoplasma fermentans Species 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 108010085650 interferon gamma receptor Proteins 0.000 abstract description 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000013566 allergen Substances 0.000 description 32
- 102100037850 Interferon gamma Human genes 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- 102000004388 Interleukin-4 Human genes 0.000 description 24
- 108090000978 Interleukin-4 Proteins 0.000 description 24
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 206010020751 Hypersensitivity Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000007815 allergy Effects 0.000 description 10
- 102000003814 Interleukin-10 Human genes 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 9
- 230000036428 airway hyperreactivity Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 108010002616 Interleukin-5 Proteins 0.000 description 7
- 102000000743 Interleukin-5 Human genes 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004199 lung function Effects 0.000 description 7
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 7
- 230000008313 sensitization Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 102000003816 Interleukin-13 Human genes 0.000 description 6
- 108090000176 Interleukin-13 Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 239000000428 dust Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000004941 influx Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014950 Eosinophilia Diseases 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 101150034459 Parpbp gene Proteins 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229960002329 methacholine Drugs 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000021 stimulant Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010040721 Flagellin Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001440840 Mikania micrantha Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229940099412 Toll-like receptor 2 agonist Drugs 0.000 description 2
- 229940123265 Toll-like receptor 6 agonist Drugs 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000212 effect on lymphocytes Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000008237 Toll-Like Receptor 6 Human genes 0.000 description 1
- 108010060826 Toll-Like Receptor 6 Proteins 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- WHLPIOPUASGRQN-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C WHLPIOPUASGRQN-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464839—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Definitions
- This invention relates to a therapeutical composition, a method of its preparation, and corresponding methods of use, especially as a vaccine within a method of treatment for tumor associated disorders, infectious disorders and transplantation associated disorders or treatment of allergic disorders.
- the invention is related to the field of immunotherapy where in general pretreated dendritic cells are used as vaccines to stimulate or modulate an individual immune response.
- DC Dendritic cells
- DC are also described to induce under the appropriate conditions an unpolarized Th-0 response, or else they may anergize T-cells which results in tolerance.
- the mechanisms involved in this plasticity are affinity and duration of MHC II-TCR interaction, the expression pattern of costimulatory molecules, and the availability of cytokines (Kalinski P, Hilkens C M, Wierenga E A, Kapsenberg M L. Immunol Today 1999; 20(12):561-7).
- antigen-pulsed DC i.e. DC loaded with antigens
- the purpose is to immunize patients in need thereof against tumors (see e.g. Brossart et al. Exp. Hematol. 291247 (2001)), infectious agents or other pathogens (see review of Moll and Berberich, J. Med. Microbiol. 291323 (2001)).
- Great efforts are made with respect to the treatment of tumors that have become resistant to conventional therapeutical means. Especially in tumor therapy it is highly desirable to induce a sufficient antigen-specific Th-1 response.
- Dendritic cells can be prepared using different techniques. For human DC the preparation derived from blood monocytes is currently the most efficient. This method generates sufficient numbers of autologous DC. Such DC have been in vitro treated with several stimulatory compounds to mature and induce proliferation of lymphocytes. E.g. DC that were treated with MALP-2 or LPS induced a marked proliferation of autologous lymphocytes, but no significant polarization of lymphocytes into T-helper (Th-1) cells (Weigt, H., Mühlradt, P. F., Emmendorffer, A., Krug, N. Braun, A., Immunobiol. 2003 May 1; 207(3): 161-8).
- Th-1 T-helper
- lipopeptides and in particular MALP-2 are useful for treating lung infections and lung tumors, e.g. by intratracheal instillation thereof (WO 02/28887).
- One object of this invention is to find a method to modulate an existing Th-2 response towards Th1 response or to provoke or enhance a Th-1 response and to influence the lymphocyte modulating potential of DC in the aforementioned direction since this is deemed to be an approach e.g. towards causative treatment of allergic disorders.
- Another object of the invention is to provide a diagnostic tool to test the immune status of a patient.
- the magnitude of an immuneresponse after in vitro Th-1 stimulation of the cells of a patient can be quantified and compared to standard values.
- the inventors now discovered that in vivo or in vitro treatment of DC or tissue containing DC with a toll-like receptor 2 and/or toll-like receptor 6 agonist in combination with an IFN ⁇ receptor agonist stimulate DC to induce a Th-1 typical response in lymphocytes.
- the DC cells used in connection with this invention can be taken from any suitable source.
- the source of DC includes progenitor derived DC, e.g., monocyte derived DC and stem cell derived DC, or DC from in viva sources, e.g., blood derived DC. Techniques to obtain DC from human blood monocytes are described e.g. in T. G. Berger et al., J. Immunol. Methods 268: 131-140 (2002).
- the DC used should preferably be derived from autologous monocytes of a person or animal to be treated with the therapeutical composition according to the invention.
- the therapeutical composition for the preparation of the therapeutical composition according to one embodiment of the present invention there is added at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist to a culture or solution of dendritic cells from any source whereupon this mixture is further used for the preparation of a therapeutical composition or as a therapeutical composition as such.
- the DC and receptor agonists as described below are cocultivated for at least 12 hours, preferably 48 hours. For the details reference is made to the examples.
- the culture of the DC may further contain growth factors, cytokines, antigens, cells and/or substances, especially salts, nutrients, or other auxiliary agents and/or drugs.
- the DC are washed after the first cultivation period and used for the further preparation of a therapeutical composition or as a therapeutical composition as such, preferably resuspended in saline, or any other physiological solution.
- the DC are then, after the first treatment with both agonists, i.e. after the first cultivation period, loaded with appropriate antigens according to established methods (e.g. Feuerstein et al. J. Immunol. Methods 245: 15-29 (2000)).
- lymphocytes which are preferably autologous or allogenic lymphocytes acquired from the peripheral blood of donors, are added from the beginning or after the first cultivation period, whereafter the DC, the lymphocytes and optionally further ingredients are cocultivated for a time period up to several days, preferably for at least 12 or 48 hours, more preferred at least 3 days, and wherein the resulting culture is used for the further preparation of a therapeutical composition or as a therapeutical composition as such.
- lymphocytes can be separated from the culture, optionally washed and used for the further preparation of a therapeutical composition or as a therapeutical composition as such, preferably resuspended in, saline, or any physiological solution.
- a pharmaceutical composition comprising effective amounts of at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent.
- the pharmaceutical composition according to the present invention allows for modulation of DC in vivo by simply administering of at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent to a person in need thereof.
- the pharmaceutical composition is adapted for inhalative administration, e.g. intratracheal instillation.
- the IFN ⁇ receptor agonist is human interferon gamma or a variant thereof, since most applications will be for human beings. In general the appropriate species-specific IFN ⁇ or variant should be used. Suitable interferon gamma receptor agonists are e.g. disclosed in Ioannovich et al. Intensive Care Med 1996 October; 22 Suppl 4:S468-73. Musial et al. Allergy. 1995 June; 50(6):520-3. Reumann. Pediatr Infect Dis J. 2001 October; 20(10):995-6. Review. Aulitzky et al. Immunobiology. 1990 June; 180(4-5):385-94.
- the term IFN ⁇ receptor agonist encompasses natural as well as synthetic molecules, including parts and derivates thereof as far as a sufficient activity to bind to the IFN ⁇ receptor is retained.
- the toll-like receptor 2 and/or 6 agonist is preferably an agonist capable to signal via both toll-like receptors 2 and 6, like e.g. MALP-2 (see below); the agonist can also be a toll-like 2 or a toll-like 6 receptor agonist as far as a sufficient stimulation of DC can be achieved.
- the TLR 2 / 6 agonist is a bisacyloxypropyl-S-cystein derivative, or a lipopeptide derived from Mycoplasma fermentans or a corresponding synthetic lipopeptide capable to stimulate macrophage in vitro or in vivo, preferably Marophage Activating Lipopeptide 2 kDa (MALP-2) or biologically active derivates thereof, shown to be less pyrogenic then LPS (Deiters et al. Infect Immun. 2003, August; 71(8):4456-62).
- Suitable MALP variants are for example described in Morr M., Takeuchi O., Akira S., Simon M. M., Mühlradt P. F., Eur. J. Immunol.
- the toll-like receptor agonist molecules can be chemically modified, for example pegylated as disclosed for different proteins in EP 0 510 356 B1 and references cited therein.
- S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-carboxy-polyethylenglykol or S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinyl-carboxy-polyethylenglykol are preferred.
- compositions according to this invention are useful as vaccines, for cell therapy and for the treatment of allergic disorders, malignancies, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.
- they contain DC and/or lymphocytes cocultivated with said DC, where the DC have acquired the property to drive a T helper cell type I response.
- the pharmaceutical composition contains effective amounts of at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or 6 agonist.
- This invention further teaches the use of DC in combination with a least one IFN ⁇ receptor agonist and at least one TLR 2 and/or 6 agonist and the appropriate antigens or antigen delivering or encoding vectors according to the respective application for the manufacture of a medicament for the treatment of allergic disorders, in particular of allergic airway disease, like asthma, e.g. in human or horses, cancer, e.g. melanoma, renal and prostate carcinoma or pancreas carcinoma, of viral infections, e.g. by HIV, Herpes and influenza, of bacterial infections, e.g. by Listeria, Salmonella, Mycobacteria, Chlamydia and Borrelia, of fungal infections, especially Candida, Aspergillus, Actinomyces.
- autoimmune disorders e.g. Lupus erythematosus, type 1 diabetes and multiple sclerosis, and of transplantation associated diseases, especially graft-versus-host disease and host-versus-graft disease.
- the medicament or the therapeutical composition of the invention may further contain pharmaceutically acceptable carriers or preservatives. That means, for medical use diluents, pharmaceutically acceptable carriers, auxiliary agents, drugs, and so on, can be added to the therapeutical composition obtained from said cells and/or mixtures to meet practical needs.
- the invention encompasses the use of at least one IFN ⁇ receptor agonist in combination with at least one TLR 2 and/or TLR 6 agonist for the treatment of DC in vivo or in vitro.
- the therapeutical composition can be applied for example intradermally, subcutaneously, intravenously, inhalatively, intranasally, intranodally or in the case of cancer by injection into or near the tumor.
- the invention also covers the use as a diagnostic tool to monitor the immune status of persons or animals. This is achieved by cocultivating DC which have been prestimulated with at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist with autologous or allogenic lymphocytes and measuring proliferation, release of molecules, cytotoxic activity and antibody formation. These parameters can be quantified and compared to standard values. A hyper- or hyporesponse to the stimuli indicates an imbalanced immune status.
- the invention relates to methods for treatment of a subject in need thereof with dendritic cells and/or lymphocytes prepared according to the methods of the present invention.
- the invention provides for a method of treating a subject with at least one IFN ⁇ receptor agonist and at least one TLR 2 and/or TLR 6 agonist.
- toxicity and therapeutical effects of the respective compounds can be determined by standard to pharmaceutical procedures in cell cultures or experimental animals, e.g. for determining the LD 50 and the ED 50 .
- the dose ratio between toxic and therapeutical effects is the therapeutic index and can be expressed as the ratio LD 50 /ED 50 .
- the dosage may vary due to various individual factors, like conditions of the subject, weight, age etc. of the subject, or the application form chosen for the administration of the therapeutical composition.
- FIG. 1 Production of the cytokines IFN-g and IL-4 in the coculture of autologous lymphocytes with allergen-pulsed (DerP1) versus unpulsed (PBS) DC. DerP1 sensitive and healthy donors are opposed. The bracket indicates a significant difference (p ⁇ 0.05) between the compared groups.
- FIG. 2 Flow cytometric analysis of DC harvested after 7 days of culture. The fluorescence profile of isotype-matched control, allergen-pulsed DC or allergen-pulsed and MALP-2+IFN-g treated DC of one representative experiment is shown for each cell surface molecule.
- FIG. 3 Production of the cytokines IL-10 (a), IL12p70 (b) and TNF- ⁇ (c) after treatment of immature DC with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g.
- the bracket indicates a significant difference (p ⁇ 0.05) between the compared groups.
- FIG. 4 Proliferative response measured by 3H-Thymidine incorporation after coculture of DC pretreated with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g and autologous lymphocytes.
- Each curve represents the mean of 6 individual experiments of titrated DC cocultured with a constant number of lymphocytes. The last point (lymphocytes) shows lymphocytes without DC.
- FIG. 5 Ratio of IFN-g production to IL-4 production after coculture of DC pretreated with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g and autologous lymphocytes.
- FIG. 6 Schematic presentation of the study design according to example 2.
- Female Balb/c mice were sensitized by i.p. injection of Ovalbumin adsorbed to Alum (controls received only Alum) on day 0, 14 and 21.
- mice were i.t.treated with NaCl, MALP-2, IFN- ⁇ or the combination of MALP-2 and IFN- ⁇ . All groups received OVA aerosol challenge on days 28 and 29. 24 hours later head-out body plethysmography was performed to measure AHR followed by animal dissection.
- FIG. 7 Detection of IL-4, IL-5, IL-13 and IL-12p70 in the BALF 24 hours after the last allergen challenge.
- Groups have been sham-sensitized and -treated (NaCl/NaCl), OVA-sensitized and NaCl treated (OVA/NaCl), sensitized and MALP-2 treated (OVA/MALP-2), sensitized and IFN- ⁇ treated (OVA/IFN- ⁇ ) or sensitized and MALP-2+IFN- ⁇ treated (OVA/MALP-2+IFN- ⁇ ).
- One asterisk gives p ⁇ 0.05, while two asterisks show p ⁇ 0.01 vs. the OVA/NaCl positive control.
- FIG. 8 Cellular composition in the broncho-alveolar lavage fluid (BALF) 24 hours after the last allergen challenge. Groups have been treated as described in FIGS. 1 and 2 . One asterisk gives p ⁇ 0.05, while two asterisks show p ⁇ 0.01 vs. the OVA/NaCl positive control.
- FIG. 9 Lung histology 24 h after the last allergen challenge. 5 ⁇ m thick cryostat section were stained with hematoxilin/eosin. Mice have been sham-sensitized and -treated (A), OVA-sensitized and NaCl-treated (B) or OVA-sensitized and treated with MALP-2+IFN- ⁇ (C).
- Figure D displays a lung from the OVA-sensitized, MALP-2+IFN- ⁇ treated group 7 days after the last allergen challenge. Image acquisition was performed using a 20-fold objective and a resolution of 0.1 ⁇ m 2 per pixel; the bar represents a 100 ⁇ m segment.
- FIG. 10 Lung function measurement 24 hours after the last allergen challenge.
- EF 50 midexpiratory airflow
- Mch methacholin
- Animals have been sham-sensitized and -treated (NaCl/NaCl), OVA-sensitized and NaCl-treated (OVA/NaCl) or OVA-sensitized and treated with MALP-2+IFN- ⁇ (OVA/MALP-2+IFN- ⁇ ).
- the vertical lines of each group give the Mch concentration that induces a 50% reduction of the EF 50 , i.e. the ED 50 .
- Sensitization to OVA without treatment induces a significant (p ⁇ 0.05) reduction of the ED 50 compared to the unsensitized, sham-treated control and to the sensitized, MALP-2+IFN- ⁇ treated group.
- An allergic reaction is characterized i.a. by an increased production of cytokines IL-4 and a decreased production of IFN ⁇ .
- a useful model is to cocultivate allergen pulsed DC with autologous lymphocytes of patients suffering from an allergic disease.
- monocytes were derived from the blood of volunteers who reacted positively to Dermatophagoides pteronyssinus allergen DerP1 in a prick test.
- Four sets of DC cultures were set up. To one part of the DC only the allergen was added (group DerP1), another part was additionally treated with MALP-2 (group DerP1+MALP-2), another part with IFN ⁇ (group DerP1+IFN-g), and yet another part with both MALP-2 and IFN ⁇ (group DerP1+MALP-2+IFN-g). Further, there was an only solvent treated, unstimulated control (PBS). After cell harvest, all these groups were incubated with autologous lymphocytes (from the same volunteers).
- Monocyte derived DC were generated as previously described (Weigt et al. Immunobiol. 207, 223-233 (2003). Briefly, blood was centrifuged to remove platelets, diluted and layered over Ficoll-Paque (Amersham Pharmacia, Uppsala, Sweden). After density gradient centrifugation, PBMC were collected, and monocytes were enriched using the MACS system and anti-CD 14 beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD14 positive fraction (monocytes) was cultured in the serum-free medium X-VIVO 15 supplemented with 100 U/ml penicillin and 100 ng/ml streptomycin (all BioWhittaker, Verviers, Belgium).
- the CD14 negative fraction containing the lymphocytes was cryopreserved in 90% FCS (GIBCO, Eggenstein-Leopoldhafen, Germany) and 10% DMSO (SIGMA, Taufkirchen, Germany).
- FCS GEBCO, Eggenstein-Leopoldhafen, Germany
- DMSO SIGMA, Taufmün, Germany
- 800 U/ml of recombinant GM-CSF and 500 U/ml of recombinant IL-4 (Strathmann Biotec, Hamburg, Germany) were added to the monocyte culture to induce DC.
- cells endocytose FITC-labeled Dextran and express the Toll-like receptors ⁇ 2 and ⁇ 6, which are associated with MALP-2 signaling.
- DC were pulsed with affinity purified house dust mite allergen adjusted to a concentration of 100 ng/ml of DerP1 or with PBS as control.
- DC were further treated with 100 pg/ml of MALP-2 synthesized and purified as described (Morr et al. Eur J Immunol 2002; 32(12):3337-47), 5000 U/ml of IFN-g (Strathmann Biotec), with both substances at the same concentrations or with PBS (control).
- the respective optimal concentrations were experimentally determined using the highest expression of stimulatory cell surface molecules as read-out system. The substances were incubated on the cells for 48 hours.
- Cytokine concentrations were determined in DC culture supernatant collected on day 7 (TNF- ⁇ , IL-10, IL-12) and in the supernatant of the coculture of DC and autologous lymphocytes collected on day 10 (IFN- ⁇ , IL-4).
- Duo-Set ELISA kits for the detection of IL-12p70, IL-10, TNF, IFN- ⁇ , IL-4 and IL-5 were purchased (R&D Systems, Wiesbaden, Germany) and performed according to the manufacturers instructions.
- DC was used for coculture experiments with autologous lymphocytes from day 7 to day 13.
- DC were harvested and washed twice.
- the cells were titrated in fresh medium in fresh round-bottom microtiterplates.
- 1 ⁇ 10 5 vital cryopreserved autologous lymphocytes were added at ratios of DC to lymphocytes from 1:3 to 1:2187 in a final volume of 200 ⁇ l in serum-free XVIVO-15. No further stimulants were given.
- the coculture was pulsed with 5 ⁇ Ci/ml 3 H-thymidine (Amersham Buchler, Braunschweig, Germany) on day 12. After 18 hours, the cells were harvested on filtermats (Canberra-Packard, Dreieich, Germany). After drying, 20 ⁇ l of liquid scintillator (Canberra-Packard) were added and the plates were sealed. Counts per minute were determined on a Topcount Microplate Scintillation Counter (Canberra-Packard).
- IL-12p70 blocking antibody R&D Systems
- DC pulsed with DerP1 induce a Th2-skewed immuneresponse in autologous lymphocytes of allergies
- DC of house dust mite allergic donors and of healthy-control donors were pulsed with DerP1, the major allergen of the house dust mite Dermatophagoides pteronyssinus. Controls remained unpulsed. After a 2 day incubation period, DC were harvested and coincubated with autologous lymphocytes. Cell culture supernatant was collected on day 3 of the coculture and analyzed for the concentrations of IFN-g and IL-4 by ELISA ( FIG. 1 ). Using unpulsed DC, IFN-g concentrations of allergies and healthy donors were comparable (7.7 pg/ml ⁇ 3.7 (allergies) vs.
- MALP-2 and IFN-g Synergistically Increase Surface Molecules Associated with Maturation of DC
- TNF, IL-10 and IL-12p70 were analysed in the cell culture supernatants by ELISA after 7 days of cell culture. Stimulation with DerP1 or with IFN-g did not influence the production of IL-10 and IL-12 compared to untreated DC.
- MALP-2 only induced IL-10 and had no effect on IL-12.
- a striking difference was observed when stimulating with MALP-2 and IFN-g: IL-12 was massively increased, which was associated with the complete reduction of IL-10 to basal levels. ( FIG. 3 a,b ).
- TNF was produced at low levels in the unstimulated control group and in the DerP1 pulsed group.
- MALP-2 and IFN-g induced a comparable moderate release, while both stimuli together more than doubled the concentration of TNF compared to the single substances ( FIG. 3 c ).
- DC were cocultured after their harvest on day 7 with autologous lymphocytes. Therefore, unbound stimulants were removed by washing, DC were seeded at various cell numbers in fresh medium and new cell culture plates, and a constant number of the cryopreserved autologous lymphocytes was added. To determine proliferation, the coculture was pulsed with 3 H-thymidine on day 12 for further 18 hours. In allergies, pulsing of DC with DerP1 airways resulted in a higher proliferative response in all preparations which was not observed in healthy control donors (data not shown). This demonstrates the induction of a secondary immuneresponse in the test system.
- mice Female Balb/c mice (Charles River, Sulzfeld, Germany) were used at the age of 6-8 weeks in all experiments. They were fed with ovalbumin-free laboratory food and tap water ad libitum and held in a regular 12 h dark/light cycle at a temperature of 22° C. Before experimental start, mice were acclimated for a period of 7 days.
- OVA-aerosols (grade V, Sigma) with a mean mass diameter of 1.49 ⁇ m were generated from a solution of 1 mg/ml OVA in 0.9% NaCl using a modified Pari Master system (Pari Maschinene, Sternberg, Germany) for 20 min.
- a lung deposition of approximately 8 ⁇ g OVA per mice in each session was calculated by a respiratory minute volume of 35 ml/min an a deposition factor of 0.15 as brought forward by Raabe et al. (Raabe, O. G., J. E. Bennick, M. E. Light, C. H. Hobbs, R. L. Thomas, and M. I. Tillery. 1973 . Toxicol. Appl. Pharmacol. 26:264-273).
- the study protocol is shown in FIG. 6 , and Tab. 3 gives the test groups.
- mice were intratracheally treated with 20 ng macrophage activating lipopeptide-2 (MALP-2, synthesized and purified as described (Morr, M., O. Takeuchi, S. Akira, M. M. Simon, and P. F. Muhlradt. 2002 . Eur. J. Immunol. 32:3337-3347), 10 4 U IFN- ⁇ (Strathman Biotec, Hamburg, Germany), or a combination of both on day 27, 24 h before the allergen challenge (see FIG. 6 ). Controls were instillated with NaCl (see Tab. 3). Therefore, animals were anaesthetized by i.p.
- MALP-2 macrophage activating lipopeptide-2
- Mch methacholine
- the aerosol concentration in the inhaled atmosphere was continuously determined during the provocation using a clean air mantle aerosol photometer.
- the photometer was gravimetrically calibrated for aerosol.
- the respiratory signals were calculated from a pneumotachograph (PTM 378/1.2, Hugo Sachs Electronics, March-Hugstetten, Germany) linked to a DP45-14 differential pressure transducer (Validyne, Northridge, USA) and amplified through a Carrier Frequency Bridge Amplifier; (Type 677, Hugo Sachs Electronics). Flow dependent respiratory signals were transduced into lung function parameters and continuously registered. For determination of bronchoconstriction, the midexpiratory airflow (EF50), i.e. the expiratory airflow (ml/s) at 50% tidal volume, was measured. Respiratory signals were analyzed using the Hem 3.4 system (Notocord systems S.A., Crossy-sur-Seine, F).
- mice were killed with an i.p. injected overdose of pentobarbital-Na (Merial, Halbergmoos, Germany) after the lung function.
- pentobarbital-Na (Merial, Halbergmoos, Germany) after the lung function.
- mice were left untouched after the last allergen challenge and kept for another 7 days. Afterwards, they were dissected in the same way as the main groups as follows. Blood was obtained via punction of the vena cava. Red blood cells were lysed by incubation with 0.9% NH 4 Cl (Sigma) in H 2 O for 10 min, white blood cells were automatically counted using an AcT8 counter (Beckman Coulter, Krefeld, Germany) and cytospins were prepared for differential cell count.
- the trachea was cannulated and broncho-alveolar lavage (BAL) was performed with 0.8 ml ice cold saline two times. BAL cells were separated by centrifugation, counted and cytospins were prepared as described above.
- the BAL fluid (BALF) was aliquoted, shock frozen in liquid nitrogen and stored at ⁇ 80° C. until the determination of cytokines.
- the lungs were filled with Tissue-Tek O.C.T. (Sakura Finetek, Zoeterwoude, Netherlands) diluted 1:2 in PBS and the trachea was ligated. Next, the right lungs were excised, subsequently shock frozen in liquid nitrogen and stored at ⁇ 80° C. for histology.
- Cytospins were stained applying the Pappenheim method according to standard protocols. Leukocyte populations of blood and BAL were manually differentiated using a microscope and 630-fold magnification. 300 cells of each sample were determined, and absolute counts of macrophages, lymphocytes, eosinophilic and neutrophilic granulocytes were calculated.
- cryostat sections were taken from frozen lungs and placed on slides. After acetone fixation (10 min. at ⁇ 20° C.) and washing in PBS, sections were stained with hematoxilin/eosin according to standard procedures and mounted in Entellan (Merck, Darmstadt, Germany). Photographies were taken using an Axioskop 2 microscope equipped with an Axiocam CCD camera and Axiovision acquisition software (all Carl Zeiss GmbH, Jena, Germany).
- Duo-Set ELISA kits for the detection of IL-4, IL-5, IL-13 and IL-12p70 in the BAL supernatant were used (R&D Systems, Wiesbaden, Germany) according to the manufacturer's instructions.
- the cytokines IL-4, IL-5, IL-13 and IL-12p70 were quantified in the BALF. Allergen sensitization resulted in the upregulation of the Th2 markers IL-4, IL-5 and IL-13 compared to the negative control, while the Th1 inducing IL-12p70 was not affected. This cytokine profile corresponds to a clear shift towards Th2 in the group injected and challenged with OVA. Local treatment with MALP-2 alone was able to reduce all Th2-markers to the level of the unsensitized negative control, but did not amplify IL-12p70.
- MALP-2 and IFN- ⁇ Improve the Lung Function of Airflow Obstructed Animals
- DC have the potential of inducing different responses in lymphocytes. Depending on DC treatment, lymphocytes get activated or anergic, polarized according to the Th1/2 model or become Th0. This potential is termed plasticity of DC (Huang et al. Science 2001; 294(5543):870-5). In this study, it was shown that only DerP1-pulsed, otherwise immature DC of house dust mite allergics induce an autologous Th2-response ( ⁇ IFN-g, ⁇ IL-4), but that equally treated DC of non-allergics have no effect on lymphocytes ( ⁇ IFN-g, ⁇ IL-4).
- MALP-2 stimulation is known to induce maturation of DC. It upregulates costimulatory cell surface molecules and induces IL-10 secretion, while IL-12p70, a cytokine pivotal for inducing Th1 responses, was not produced.
- MALP-2 treatment of DC leads to an enhanced lymphocyte proliferation, but does not influence the Th-polarization compared to unstimulated control-DC (Weigt et al. Immunobiol. 207, 1-11 (2003).
- IFNg in contrast, is described to reduce immunostimulatory capacity of DC by downregulating costimulatory molecules (Rongcun et al. Cytokine 1998 October; 10(10):747-55).
- Example 2 used a well established murine model of allergic airway inflammation and AHR, with OVA as allergen, to examine whether our earlier in vitro findings could be extended to an in vivo scenario.
- NaCl/ OVA/ OVA/ OVA/ groups NaCl NaCl MALP-2 IFN- ⁇ MALP-2 + IFN- ⁇ sensitization/booster NaCl OVA OVA OVA OVA challenge OVA OVA OVA OVA OVA OVA OVA OVA OVA OVA treatment (i.t.) NaCl NaCl 20 ng MALP-2 10 4 U IFN- ⁇ 20 ng MALP-2 10 4 U IFN- ⁇ animal number (n) 8 16 8 8 16
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method for the preparation of a therapeutical composition, in particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll like receptor 2 and/or TLR 6 agonist and using these pretreated dendritic cells for the preparation of a therapeutical composition. Moreover, the present invention relates to a therapeutical composition containing dendritic cells and the use thereof for the treatment of various diseases and disorders.
Description
- This invention relates to a therapeutical composition, a method of its preparation, and corresponding methods of use, especially as a vaccine within a method of treatment for tumor associated disorders, infectious disorders and transplantation associated disorders or treatment of allergic disorders.
- The invention is related to the field of immunotherapy where in general pretreated dendritic cells are used as vaccines to stimulate or modulate an individual immune response.
- Dendritic cells (DC) are considered to be the most important antigen presenting cells of the immune system. They sample antigen at the body's environmental interface and, under the appropriate conditions, mature and migrate to the lymphatic organs were they induce primary and enhance secondary immune responses. The conditions under which DC maturation is induced determine the outcome of the immune response. As an example, bacterial infection associated with inflammatory conditions leads to a T-helper (Th-)-1 response which is characterized by IFNγ producing Th-cells. In contrast, parasite infections for example instruct DC to mount a Th-2 response with IL-4 producing Th-cells.
- DC are also described to induce under the appropriate conditions an unpolarized Th-0 response, or else they may anergize T-cells which results in tolerance. The mechanisms involved in this plasticity are affinity and duration of MHC II-TCR interaction, the expression pattern of costimulatory molecules, and the availability of cytokines (Kalinski P, Hilkens C M, Wierenga E A, Kapsenberg M L. Immunol Today 1999; 20(12):561-7).
- The application of so called antigen-pulsed DC, i.e. DC loaded with antigens, is an extensively explored field (see for example the review of Yao, Platell, Hall, Surg. 72501 (2002)). The purpose is to immunize patients in need thereof against tumors (see e.g. Brossart et al. Exp. Hematol. 291247 (2001)), infectious agents or other pathogens (see review of Moll and Berberich, J. Med. Microbiol. 291323 (2001)). Great efforts are made with respect to the treatment of tumors that have become resistant to conventional therapeutical means. Especially in tumor therapy it is highly desirable to induce a sufficient antigen-specific Th-1 response.
- A further application of pretreated DC, i.e. for the treatment of allergic diseases is discussed in Smits et al., Int. Arch. Allergy Immunol. 126:102 (2001). Allergic type I disorders are DC induced. They are Th-2-mediated immune reactions against harmless antigens. A therapeutic aim is to redirect this response towards a Th-1 reaction, which would abolish the allergic symptoms.
- Dendritic cells can be prepared using different techniques. For human DC the preparation derived from blood monocytes is currently the most efficient. This method generates sufficient numbers of autologous DC. Such DC have been in vitro treated with several stimulatory compounds to mature and induce proliferation of lymphocytes. E.g. DC that were treated with MALP-2 or LPS induced a marked proliferation of autologous lymphocytes, but no significant polarization of lymphocytes into T-helper (Th-1) cells (Weigt, H., Mühlradt, P. F., Emmendorffer, A., Krug, N. Braun, A., Immunobiol. 2003 May 1; 207(3): 161-8). In general, the stimulation of mature DC through toll-like receptors alone may not suffice to induce a Th-1 immune response (Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu Y J, O'Garra A. J Exp Med. 2003 Jan. 6; 197(1):101-9; Eisenbarth S C, Piggott D A, Huleatt J W, Visintin I, Herrick C A, Bottomly K. J Exp Med. 2002 Dec. 16; 196(12): 1645-51; Re F, Strominger J L. J Biol Chem. 2001 Oct. 5; 276(40):37692-9). Recently, Means et al. J Immunol. 2003 May 15; 170(10):5165-75 described that bacterial flagellin, acting via
TLR 5, in combination with IFNβ can stimulate chemokine expression while INFβ or flagellin alone failed to induce said expression. - With respect to the use of MALP-2 in therapeutical applications, it is known that lipopeptides and in particular MALP-2 are useful for treating lung infections and lung tumors, e.g. by intratracheal instillation thereof (WO 02/28887).
- In view of the above, there is still an urgent need to provoke or enhance Th-1-type immune responses in vitro and in vivo.
- One object of this invention is to find a method to modulate an existing Th-2 response towards Th1 response or to provoke or enhance a Th-1 response and to influence the lymphocyte modulating potential of DC in the aforementioned direction since this is deemed to be an approach e.g. towards causative treatment of allergic disorders.
- It is a further object of the invention to provide a therapeutical composition for use in the treatment of allergic disorders, in tumor therapy and for the treatment of infectious diseases caused by viruses, bacteria, fungi or parasites. Another object of the invention is to provide a diagnostic tool to test the immune status of a patient. Here, the magnitude of an immuneresponse after in vitro Th-1 stimulation of the cells of a patient can be quantified and compared to standard values.
- The inventors now discovered that in vivo or in vitro treatment of DC or tissue containing DC with a toll-
like receptor 2 and/or toll-like receptor 6 agonist in combination with an IFNγ receptor agonist stimulate DC to induce a Th-1 typical response in lymphocytes. - Therefore, according to one aspect of the present invention there is provided a method of treatment of a subject in need thereof with dendritic cells pretreated in a manner as described below:
-
- 1. DC are generated ex vivo in cell culture according to standard procedures, and stimulated with a toll-
like receptor 2 and/or toll-like receptor 6 agonist in combination with an IFNγ receptor agonist. The concentrations of the agonists can be adjusted by the skilled practitioner. Cell culture can be carried out in the presence of antigen or antigen delivering or encoding vectors according to the practitioners need. After incubation (usually 7 days, with the last 48 h in presence of the stimuli), cells are either administered freshly into the patient via all available routes and/or are cryopreserved. They can be thawed and used when required according to the practitioners need. - 2. DC are generated as mentioned above. Afterwards, DC are cocultured with leukocytes, preferably autologous lymphocytes. This mixture of cells will than be applied to the patient.
- 3. The cell mixture described in 2. will be separated after coculture, and each isolated cell population will be applied separately.
- 1. DC are generated ex vivo in cell culture according to standard procedures, and stimulated with a toll-
- The DC cells used in connection with this invention can be taken from any suitable source. The source of DC includes progenitor derived DC, e.g., monocyte derived DC and stem cell derived DC, or DC from in viva sources, e.g., blood derived DC. Techniques to obtain DC from human blood monocytes are described e.g. in T. G. Berger et al., J. Immunol. Methods 268: 131-140 (2002). The DC used should preferably be derived from autologous monocytes of a person or animal to be treated with the therapeutical composition according to the invention.
- For the preparation of the therapeutical composition according to one embodiment of the present invention there is added at least one IFNγ receptor agonist and at least one
TLR 2 and/orTLR 6 agonist to a culture or solution of dendritic cells from any source whereupon this mixture is further used for the preparation of a therapeutical composition or as a therapeutical composition as such. The DC and receptor agonists as described below are cocultivated for at least 12 hours, preferably 48 hours. For the details reference is made to the examples. - The culture of the DC may further contain growth factors, cytokines, antigens, cells and/or substances, especially salts, nutrients, or other auxiliary agents and/or drugs.
- According to a further embodiment of the invention the DC are washed after the first cultivation period and used for the further preparation of a therapeutical composition or as a therapeutical composition as such, preferably resuspended in saline, or any other physiological solution.
- According to another embodiment the DC are then, after the first treatment with both agonists, i.e. after the first cultivation period, loaded with appropriate antigens according to established methods (e.g. Feuerstein et al. J. Immunol. Methods 245: 15-29 (2000)).
- According to yet another embodiment of the invention lymphocytes, which are preferably autologous or allogenic lymphocytes acquired from the peripheral blood of donors, are added from the beginning or after the first cultivation period, whereafter the DC, the lymphocytes and optionally further ingredients are cocultivated for a time period up to several days, preferably for at least 12 or 48 hours, more preferred at least 3 days, and wherein the resulting culture is used for the further preparation of a therapeutical composition or as a therapeutical composition as such.
- After these steps the lymphocytes can be separated from the culture, optionally washed and used for the further preparation of a therapeutical composition or as a therapeutical composition as such, preferably resuspended in, saline, or any physiological solution.
- According to a second aspect of the invention, there is provided a pharmaceutical composition comprising effective amounts of at least one IFNγ receptor agonist and at least one
TLR 2 and/orTLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent. - This means using the pharmaceutical composition according to the present invention allows for modulation of DC in vivo by simply administering of at least one IFNγ receptor agonist and at least one
TLR 2 and/orTLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent to a person in need thereof. Preferably, the pharmaceutical composition is adapted for inhalative administration, e.g. intratracheal instillation. - In a preferred embodiment the IFNγ receptor agonist is human interferon gamma or a variant thereof, since most applications will be for human beings. In general the appropriate species-specific IFNγ or variant should be used. Suitable interferon gamma receptor agonists are e.g. disclosed in Ioannovich et al. Intensive Care Med 1996 October; 22 Suppl 4:S468-73. Musial et al. Allergy. 1995 June; 50(6):520-3. Reumann. Pediatr Infect Dis J. 2001 October; 20(10):995-6. Review. Aulitzky et al. Immunobiology. 1990 June; 180(4-5):385-94. The term IFNγ receptor agonist encompasses natural as well as synthetic molecules, including parts and derivates thereof as far as a sufficient activity to bind to the IFNγ receptor is retained.
- The toll-
like receptor 2 and/or 6 agonist is preferably an agonist capable to signal via both toll-like receptors - In a preferred embodiment the
TLR 2/6 agonist is a bisacyloxypropyl-S-cystein derivative, or a lipopeptide derived from Mycoplasma fermentans or a corresponding synthetic lipopeptide capable to stimulate macrophage in vitro or in vivo, preferablyMarophage Activating Lipopeptide 2 kDa (MALP-2) or biologically active derivates thereof, shown to be less pyrogenic then LPS (Deiters et al. Infect Immun. 2003, August; 71(8):4456-62). Suitable MALP variants are for example described in Morr M., Takeuchi O., Akira S., Simon M. M., Mühlradt P. F., Eur. J. Immunol. 2002, 32:3337-3347 and references cited therein. The toll-like receptor agonist molecules can be chemically modified, for example pegylated as disclosed for different proteins inEP 0 510 356 B1 and references cited therein. In particular, S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-carboxy-polyethylenglykol or S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinyl-carboxy-polyethylenglykol are preferred. - Thus, according to an important aspect of the invention there are provided new therapeutical compositions, which are e.g. obtainable by the methods disclosed above.
- The therapeutical compositions according to this invention are useful as vaccines, for cell therapy and for the treatment of allergic disorders, malignancies, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation. In one aspect, they contain DC and/or lymphocytes cocultivated with said DC, where the DC have acquired the property to drive a T helper cell type I response. In a second aspect of the invention, the pharmaceutical composition contains effective amounts of at least one IFNγ receptor agonist and at least one
TLR 2 and/or 6 agonist. - This invention further teaches the use of DC in combination with a least one IFNγ receptor agonist and at least one
TLR 2 and/or 6 agonist and the appropriate antigens or antigen delivering or encoding vectors according to the respective application for the manufacture of a medicament for the treatment of allergic disorders, in particular of allergic airway disease, like asthma, e.g. in human or horses, cancer, e.g. melanoma, renal and prostate carcinoma or pancreas carcinoma, of viral infections, e.g. by HIV, Herpes and influenza, of bacterial infections, e.g. by Listeria, Salmonella, Mycobacteria, Chlamydia and Borrelia, of fungal infections, especially Candida, Aspergillus, Actinomyces. Further for the treatment of autoimmune disorders, e.g. Lupus erythematosus,type 1 diabetes and multiple sclerosis, and of transplantation associated diseases, especially graft-versus-host disease and host-versus-graft disease. - The medicament or the therapeutical composition of the invention may further contain pharmaceutically acceptable carriers or preservatives. That means, for medical use diluents, pharmaceutically acceptable carriers, auxiliary agents, drugs, and so on, can be added to the therapeutical composition obtained from said cells and/or mixtures to meet practical needs.
- In general, the invention encompasses the use of at least one IFNγ receptor agonist in combination with at least one
TLR 2 and/orTLR 6 agonist for the treatment of DC in vivo or in vitro. - For all embodiments of the invention described the therapeutical composition can be applied for example intradermally, subcutaneously, intravenously, inhalatively, intranasally, intranodally or in the case of cancer by injection into or near the tumor.
- The invention also covers the use as a diagnostic tool to monitor the immune status of persons or animals. This is achieved by cocultivating DC which have been prestimulated with at least one IFNγ receptor agonist and at least one
TLR 2 and/orTLR 6 agonist with autologous or allogenic lymphocytes and measuring proliferation, release of molecules, cytotoxic activity and antibody formation. These parameters can be quantified and compared to standard values. A hyper- or hyporesponse to the stimuli indicates an imbalanced immune status. - Furthermore, the invention relates to methods for treatment of a subject in need thereof with dendritic cells and/or lymphocytes prepared according to the methods of the present invention. In addition, the invention provides for a method of treating a subject with at least one IFNγ receptor agonist and at least one
TLR 2 and/orTLR 6 agonist. - As to the effective dose, toxicity and therapeutical effects of the respective compounds can be determined by standard to pharmaceutical procedures in cell cultures or experimental animals, e.g. for determining the LD50 and the ED50. The dose ratio between toxic and therapeutical effects is the therapeutic index and can be expressed as the ratio LD50/ED50. Of course, the dosage may vary due to various individual factors, like conditions of the subject, weight, age etc. of the subject, or the application form chosen for the administration of the therapeutical composition.
-
FIG. 1 Production of the cytokines IFN-g and IL-4 in the coculture of autologous lymphocytes with allergen-pulsed (DerP1) versus unpulsed (PBS) DC. DerP1 sensitive and healthy donors are opposed. The bracket indicates a significant difference (p≦0.05) between the compared groups. -
FIG. 2 Flow cytometric analysis of DC harvested after 7 days of culture. The fluorescence profile of isotype-matched control, allergen-pulsed DC or allergen-pulsed and MALP-2+IFN-g treated DC of one representative experiment is shown for each cell surface molecule. -
FIG. 3 Production of the cytokines IL-10 (a), IL12p70 (b) and TNF-α (c) after treatment of immature DC with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g. The bracket indicates a significant difference (p≦0.05) between the compared groups. -
FIG. 4 Proliferative response measured by 3H-Thymidine incorporation after coculture of DC pretreated with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g and autologous lymphocytes. Each curve represents the mean of 6 individual experiments of titrated DC cocultured with a constant number of lymphocytes. The last point (lymphocytes) shows lymphocytes without DC. -
FIG. 5 Ratio of IFN-g production to IL-4 production after coculture of DC pretreated with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g and autologous lymphocytes. -
FIG. 6 Schematic presentation of the study design according to example 2. Female Balb/c mice were sensitized by i.p. injection of Ovalbumin adsorbed to Alum (controls received only Alum) onday day 27, mice were i.t.treated with NaCl, MALP-2, IFN-γ or the combination of MALP-2 and IFN-γ. All groups received OVA aerosol challenge ondays -
FIG. 7 Detection of IL-4, IL-5, IL-13 and IL-12p70 in the BALF 24 hours after the last allergen challenge. Groups have been sham-sensitized and -treated (NaCl/NaCl), OVA-sensitized and NaCl treated (OVA/NaCl), sensitized and MALP-2 treated (OVA/MALP-2), sensitized and IFN-γ treated (OVA/IFN-γ) or sensitized and MALP-2+IFN-γ treated (OVA/MALP-2+IFN-γ). One asterisk gives p<0.05, while two asterisks show p<0.01 vs. the OVA/NaCl positive control. -
FIG. 8 Cellular composition in the broncho-alveolar lavage fluid (BALF) 24 hours after the last allergen challenge. Groups have been treated as described inFIGS. 1 and 2 . One asterisk gives p<0.05, while two asterisks show p<0.01 vs. the OVA/NaCl positive control. -
FIG. 9 Lung histology 24 h after the last allergen challenge. 5 μm thick cryostat section were stained with hematoxilin/eosin. Mice have been sham-sensitized and -treated (A), OVA-sensitized and NaCl-treated (B) or OVA-sensitized and treated with MALP-2+IFN-γ (C). Figure D displays a lung from the OVA-sensitized, MALP-2+IFN-γ treated group 7 days after the last allergen challenge. Image acquisition was performed using a 20-fold objective and a resolution of 0.1 μm2 per pixel; the bar represents a 100 μm segment. -
FIG. 10 Lung function measurement 24 hours after the last allergen challenge. The course of the midexpiratory airflow (EF50) in dependence of different concentrations of methacholin (Mch) is shown. Animals have been sham-sensitized and -treated (NaCl/NaCl), OVA-sensitized and NaCl-treated (OVA/NaCl) or OVA-sensitized and treated with MALP-2+IFN-γ (OVA/MALP-2+IFN-γ). The vertical lines of each group give the Mch concentration that induces a 50% reduction of the EF50, i.e. the ED50. Sensitization to OVA without treatment induces a significant (p<0.05) reduction of the ED50 compared to the unsensitized, sham-treated control and to the sensitized, MALP-2+IFN-γ treated group. - Table Legends
- Tab. 1 Flow cytometric analysis of DC after treatment with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g for 48 hours. The mean±SEM of the median fluorescence intensities of 6 individual experiments is shown.
- Tab. 2 Production of the cytokines IFN-γ and IL-4 in the coculture of DC pretreated with PBS, DerP1, DerP1+MALP-2, DerP1+IFN-g or DerP1+MALP-2+IFN-g and autologous lymphocytes. The mean±SEM of 6 individual experiments is shown.
- Tab. 3 Description of the experimental group
- An allergic reaction is characterized i.a. by an increased production of cytokines IL-4 and a decreased production of IFNγ. To mimic the situation in vitro a useful model is to cocultivate allergen pulsed DC with autologous lymphocytes of patients suffering from an allergic disease.
- For this purpose monocytes were derived from the blood of volunteers who reacted positively to Dermatophagoides pteronyssinus allergen DerP1 in a prick test. Four sets of DC cultures were set up. To one part of the DC only the allergen was added (group DerP1), another part was additionally treated with MALP-2 (group DerP1+MALP-2), another part with IFNγ (group DerP1+IFN-g), and yet another part with both MALP-2 and IFNγ (group DerP1+MALP-2+IFN-g). Further, there was an only solvent treated, unstimulated control (PBS). After cell harvest, all these groups were incubated with autologous lymphocytes (from the same volunteers).
- The results are discussed below with reference to the figures and the example.
- Patients
- Blood was collected from, if not otherwise mentioned, 6 allergic patients with a positive skin-prick test response to affinity purified DerP1 (ALK Scherax, Hamburg, Germany), the major allergen of the house-dust mite Dermatophagoides pteronyssinus. A positive response was defined by a wheal of 3 mm or greater. 0.9% NaCl solution served as negative control, histamine as positive control. Blood of 6 donors with a negative test was used in control experiments. All donors gave their informed consent. The study was approved by the ethics committee of the Hannover Medical School.
- Generation of DC
- Monocyte derived DC were generated as previously described (Weigt et al. Immunobiol. 207, 223-233 (2003). Briefly, blood was centrifuged to remove platelets, diluted and layered over Ficoll-Paque (Amersham Pharmacia, Uppsala, Sweden). After density gradient centrifugation, PBMC were collected, and monocytes were enriched using the MACS system and anti-CD 14 beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD14 positive fraction (monocytes) was cultured in the serum-free medium X-VIVO 15 supplemented with 100 U/ml penicillin and 100 ng/ml streptomycin (all BioWhittaker, Verviers, Belgium). The CD14 negative fraction containing the lymphocytes was cryopreserved in 90% FCS (GIBCO, Eggenstein-Leopoldhafen, Germany) and 10% DMSO (SIGMA, Taufkirchen, Germany). On
day 1 andday 5 after isolation, 800 U/ml of recombinant GM-CSF and 500 U/ml of recombinant IL-4 (Strathmann Biotec, Hamburg, Germany) were added to the monocyte culture to induce DC. Onday 5, cells endocytose FITC-labeled Dextran and express the Toll-like receptors −2 and −6, which are associated with MALP-2 signaling. - Stimulation of DC
- On
day 5 of the culture, DC were pulsed with affinity purified house dust mite allergen adjusted to a concentration of 100 ng/ml of DerP1 or with PBS as control. DC were further treated with 100 pg/ml of MALP-2 synthesized and purified as described (Morr et al. Eur J Immunol 2002; 32(12):3337-47), 5000 U/ml of IFN-g (Strathmann Biotec), with both substances at the same concentrations or with PBS (control). The respective optimal concentrations were experimentally determined using the highest expression of stimulatory cell surface molecules as read-out system. The substances were incubated on the cells for 48 hours. - Flow Cytometric Analysis of DC
- For immunophenotyping, an aliquot of DC was harvested after 7 days of culture and washed in PBS supplemented with 0.5% FCS and 10 mM NaN3 (SIGMA, Taufkirchen, Germany). After 30-minute-incubation at 4° C. with one of the following combination of labeled murine mAbs (isotype control FITC/isotype control PE, anti-CD83 FITC, anti-CD86 FITC/anti-CD40 PE, anti-CD 80 FITC/anti-HLA-DR PE, anti-CD1a FITC/anti-CD14 PE (all BD Biosciences, Heidelberg, Germany)) cells were washed and analysed on a EPICS XL-MCL (Beckmann Coulter, Krefeld, Germany) flow cytometer. Data were processed with the Expo 32 cytometer software (Beckmann Coulter). The expression of the cell surface molecules was shown in 1 parameter Histograms (
FIG. 2 ) or evaluated using the median of fluorescence intensity (MFI) after subtraction of the values of the isotype control (Tab. 1). - Determination of Cytokines
- Cytokine concentrations were determined in DC culture supernatant collected on day 7 (TNF-α, IL-10, IL-12) and in the supernatant of the coculture of DC and autologous lymphocytes collected on day 10 (IFN-γ, IL-4). Duo-Set ELISA kits for the detection of IL-12p70, IL-10, TNF, IFN-γ, IL-4 and IL-5 were purchased (R&D Systems, Wiesbaden, Germany) and performed according to the manufacturers instructions.
- Coculture of DC with Autologous Lymphocytes
- A portion of DC was used for coculture experiments with autologous lymphocytes from day 7 to
day 13. To remove free stimulants, DC were harvested and washed twice. The cells were titrated in fresh medium in fresh round-bottom microtiterplates. 1×105 vital cryopreserved autologous lymphocytes were added at ratios of DC to lymphocytes from 1:3 to 1:2187 in a final volume of 200 μl in serum-free XVIVO-15. No further stimulants were given. - Proliferation Assay
- The coculture was pulsed with 5 μCi/ml 3H-thymidine (Amersham Buchler, Braunschweig, Germany) on
day 12. After 18 hours, the cells were harvested on filtermats (Canberra-Packard, Dreieich, Germany). After drying, 20 μl of liquid scintillator (Canberra-Packard) were added and the plates were sealed. Counts per minute were determined on a Topcount Microplate Scintillation Counter (Canberra-Packard). - Blocking of IL-12p70 in the Coculture
- Directly after preparing the coculture (day 7), an IL-12p70 blocking antibody (R&D Systems) was added in a final concentration of 3 μg/ml. Controls using an unspecific isotype control antibody (R&D Systems) were included. The same concentration of antibodies was again given after 3 days (day 10). IL-12p70 blocking was performed in the coculture of DC pretreated with DerP1, MALP-2 and IFN-g with autologous lymphocytes of 3 individual experiments.
- Statistical Analysis
- Data are presented as the mean of all experiments±SEM. The paired student t-test was applied for statistical analysis. From respective controls, differences of p≦0.05 were considered significant.
- Results
- DC pulsed with DerP1 induce a Th2-skewed immuneresponse in autologous lymphocytes of allergies
- To build up a test system to evaluate the potential of DC to modulate allergic immunoreaction, DC of house dust mite allergic donors and of healthy-control donors were pulsed with DerP1, the major allergen of the house dust mite Dermatophagoides pteronyssinus. Controls remained unpulsed. After a 2 day incubation period, DC were harvested and coincubated with autologous lymphocytes. Cell culture supernatant was collected on
day 3 of the coculture and analyzed for the concentrations of IFN-g and IL-4 by ELISA (FIG. 1 ). Using unpulsed DC, IFN-g concentrations of allergies and healthy donors were comparable (7.7 pg/ml±3.7 (allergies) vs. 11.6 pg/ml±2.5 (healthy)). In allergics, pretreatment of DC with DerP1 resulted in a significant reduction of IFN-g (3.6 pg/ml±5.1), while no change was observed in non-allergics (8.7 pg/ml±6.6). Consequently, IL-4 concentration was below the detection limit of the ELISA in healthy donors, whether DC have been pulsed or not. In Contrast, DerP1 pretreated DC induced a significant upregulation of IL-4 (13.6 pg/ml±7.3) in allergies compared to unpulsed DC (9.0 pg/ml±5.8). - MALP-2 and IFN-g Synergistically Increase Surface Molecules Associated with Maturation of DC
- To test the influence of DerP1, MALP-2 and IFN-g on DC maturation, immature cells (day 5) of allergies were flow cytometrically analyzed after 48 h of incubation with the substances. The surface expressions of CD80, CD86,
CD 40, HLA-DR, CD83, CD14 and CD1a were determined. Pulsing of DC with DerP1 had no effect on the expression of the surface molecules compared to untreated DC. MALP-2 significantly upregulatedCD 40,CD 80,CD 83 and CD86, while IFN-g upregulated only HLA-DR. Using both substances to stimulate DC, a strong synergistic amplification ofCD 40,CD 80,CD 83 and CD86 and HLA-DR was observed. Expression of CD 1a as well as the low-level expression ofCD 14 was not affected (FIG. 2 ). A table giving the mean fluorescence intensities of all experiments is shown (Tab. 1). - Induction of IL-12p70 by Combined MALP-2 and IFN-g is Associated with a Reduction of IL-10
- To further analyze the maturing effect of MALP-2 and IFN-g treatment, the production of TNF, IL-10 and IL-12p70 were analysed in the cell culture supernatants by ELISA after 7 days of cell culture. Stimulation with DerP1 or with IFN-g did not influence the production of IL-10 and IL-12 compared to untreated DC. MALP-2 only induced IL-10 and had no effect on IL-12. A striking difference was observed when stimulating with MALP-2 and IFN-g: IL-12 was massively increased, which was associated with the complete reduction of IL-10 to basal levels. (
FIG. 3 a,b). TNF was produced at low levels in the unstimulated control group and in the DerP1 pulsed group. MALP-2 and IFN-g induced a comparable moderate release, while both stimuli together more than doubled the concentration of TNF compared to the single substances (FIG. 3 c). - MALP-2 and IFN-g Synergistically Increase Allergen-Associated Proliferation
- To assess the functional effects of MALP-2 and IFN-g treatment, DC were cocultured after their harvest on day 7 with autologous lymphocytes. Therefore, unbound stimulants were removed by washing, DC were seeded at various cell numbers in fresh medium and new cell culture plates, and a constant number of the cryopreserved autologous lymphocytes was added. To determine proliferation, the coculture was pulsed with 3H-thymidine on
day 12 for further 18 hours. In allergies, pulsing of DC with DerP1 airways resulted in a higher proliferative response in all preparations which was not observed in healthy control donors (data not shown). This demonstrates the induction of a secondary immuneresponse in the test system. Using DC of allergies, allergen pulsing exerted only a very weak effect on lymphocyte proliferation. Pretreatment of pulsed DC with IFN-g increased proliferation, which was exceeded by MALP-2. The strongest response however could be measured by stimulating DC with allergen and both substances (FIG. 4 ). - Combined MALP-2 and IFN-g Pretreatment Shifts the Th2-Skewed Immune Response to Th1
- To analyze the effect of MALP-2 and IFN-g pretreatment on the allergen-dependent Th2 skewed immune response using cells of allergic donors, the cytokines IFN-g and IL-4 were measured in the supernatant of the coculture. For this experiment, an optimal titration ratio of 1:3 (DC:lymphocytes) was used. As here described, DerP1-pulsing induced an increase in IL-4 and a reduction of IFN-g. Additional MALP-2 pretreatment reduced IL-4 to control levels and lowered IFN-g less compared to allergen pulsed DC, resulting in minor skewing. IFN-g pretreatment had little effect on IL-4, but heightened lymphocyte IFN-g production. This effect was strongly excelled by stimulating DC with MALP-2 and IFN-g: While IL-4 was not even doubled, IFN-g production increased more than 50-fold compared to only allergen pulsed DC, showing the characteristics of a Th1 immuneresponse.
- Animals
- Female Balb/c mice (Charles River, Sulzfeld, Germany) were used at the age of 6-8 weeks in all experiments. They were fed with ovalbumin-free laboratory food and tap water ad libitum and held in a regular 12 h dark/light cycle at a temperature of 22° C. Before experimental start, mice were acclimated for a period of 7 days.
- Sensitization and Allergen Challenge of Mice
- Animals were sensitized and challenged as previously described (Glaab, T., A. Daser, A. Braun, U. Neuhaus-Steinmetz, H. Fabel, Y. Alarie, and H. Renz. 2001. Am. J. Physiol Lung Cell Mol. Physiol 280:L565-L573). Briefly, 10 μg ovalbumin (OVA, grade VI, Sigma, Müchen, Germany) was adsorbed to 1 mg Imject Alum (Pierce, Rockford, USA) in a total volume of 200 μl 0.9% NaCl solution and intraperitonealy injected three times on
days days FIG. 6 , and Tab. 3 gives the test groups. - Treatment of Mice
- To modulate the allergic response, mice were intratracheally treated with 20 ng macrophage activating lipopeptide-2 (MALP-2, synthesized and purified as described (Morr, M., O. Takeuchi, S. Akira, M. M. Simon, and P. F. Muhlradt. 2002. Eur. J. Immunol. 32:3337-3347), 104 U IFN-γ (Strathman Biotec, Hamburg, Germany), or a combination of both on
day 27, 24 h before the allergen challenge (seeFIG. 6 ). Controls were instillated with NaCl (see Tab. 3). Therefore, animals were anaesthetized by i.p. injection of 200 μl 0.66% Propofol (Bbraun, Melsungen, Germany) and 60 s inhalation of 4% Halothan (Sigma). The trachea was cannulated under direct vision, and a total volume of 50 μl containing the substances was instillated using a syringe. - Lung Function Measurement
- 24 hours after the last allergen challenge, airway hyperreactivity to methacholine (Mch) was determined in non-anaesthetized spontaneously breathing animals using head-out body plethysmography, as described before (Glaab, T., A. Daser, A. Braun, U. Neuhaus-Steinmetz, H. Fabel, Y. Alarie, and H. Renz. 2001. Am. J. Physiol Lung Cell Mol. Physiol 280:L565-L573). Baseline measurements were followed by provocation with increasing doses of Mch diluted in 0.9% NaCl. MCh aerosols were generated by a Pari Master aerosol generator (Pari-Werke). The aerosol concentration in the inhaled atmosphere was continuously determined during the provocation using a clean air mantle aerosol photometer. The photometer was gravimetrically calibrated for aerosol. The respiratory signals were calculated from a pneumotachograph (PTM 378/1.2, Hugo Sachs Electronics, March-Hugstetten, Germany) linked to a DP45-14 differential pressure transducer (Validyne, Northridge, USA) and amplified through a Carrier Frequency Bridge Amplifier; (Type 677, Hugo Sachs Electronics). Flow dependent respiratory signals were transduced into lung function parameters and continuously registered. For determination of bronchoconstriction, the midexpiratory airflow (EF50), i.e. the expiratory airflow (ml/s) at 50% tidal volume, was measured. Respiratory signals were analyzed using the Hem 3.4 system (Notocord systems S.A., Crossy-sur-Seine, F).
- Animal Dissection
- Mice were killed with an i.p. injected overdose of pentobarbital-Na (Merial, Halbergmoos, Germany) after the lung function. In a satellite group, mice were left untouched after the last allergen challenge and kept for another 7 days. Afterwards, they were dissected in the same way as the main groups as follows. Blood was obtained via punction of the vena cava. Red blood cells were lysed by incubation with 0.9% NH4Cl (Sigma) in H2O for 10 min, white blood cells were automatically counted using an AcT8 counter (Beckman Coulter, Krefeld, Germany) and cytospins were prepared for differential cell count. The trachea was cannulated and broncho-alveolar lavage (BAL) was performed with 0.8 ml ice cold saline two times. BAL cells were separated by centrifugation, counted and cytospins were prepared as described above. The BAL fluid (BALF) was aliquoted, shock frozen in liquid nitrogen and stored at −80° C. until the determination of cytokines. After BAL, the lungs were filled with Tissue-Tek O.C.T. (Sakura Finetek, Zoeterwoude, Netherlands) diluted 1:2 in PBS and the trachea was ligated. Next, the right lungs were excised, subsequently shock frozen in liquid nitrogen and stored at −80° C. for histology.
- Differential Cell Count
- Cytospins were stained applying the Pappenheim method according to standard protocols. Leukocyte populations of blood and BAL were manually differentiated using a microscope and 630-fold magnification. 300 cells of each sample were determined, and absolute counts of macrophages, lymphocytes, eosinophilic and neutrophilic granulocytes were calculated.
- Histology
- 5 μm thick cryostat sections were taken from frozen lungs and placed on slides. After acetone fixation (10 min. at −20° C.) and washing in PBS, sections were stained with hematoxilin/eosin according to standard procedures and mounted in Entellan (Merck, Darmstadt, Germany). Photographies were taken using an
Axioskop 2 microscope equipped with an Axiocam CCD camera and Axiovision acquisition software (all Carl Zeiss GmbH, Jena, Germany). - ELISA
- Duo-Set ELISA kits for the detection of IL-4, IL-5, IL-13 and IL-12p70 in the BAL supernatant were used (R&D Systems, Wiesbaden, Germany) according to the manufacturer's instructions.
- Statistical Analysis
- To compare all groups to the OVA sensitized and NaCl treated positive control, the Dunett's test for multiple comparisons was used. One asterisk (*) depicts p values ≦0.05, while two asterisks (**) give p values ≦0.01. Statistical analysis was performed using the software Prism 3.0 (GraphPad, San Diego, USA). Data are expressed as mean±SEM.
- Results
- MALP-2 and IFN-γ Abolish the Allergen Induced Cytokine Milieu
- To test if local treatment with MALP-2 and IFN-γ is associated with a modulation of the allergen induced Th2 skew, the cytokines IL-4, IL-5, IL-13 and IL-12p70 were quantified in the BALF. Allergen sensitization resulted in the upregulation of the Th2 markers IL-4, IL-5 and IL-13 compared to the negative control, while the Th1 inducing IL-12p70 was not affected. This cytokine profile corresponds to a clear shift towards Th2 in the group injected and challenged with OVA. Local treatment with MALP-2 alone was able to reduce all Th2-markers to the level of the unsensitized negative control, but did not amplify IL-12p70. The combination of MALP-2 and IFN-γ also reduced Th2 cytokines, but only this treatment concomitantly induced IL-12p70. IFN-γ treatment alone reduced the levels of IL-5 and IL-13 in BAL, but did not affect IL-4 and failed to induce IL-12p70 (
FIG. 7 ). - Modulation of the Cellular Composition of BAL and Tissue
- Next, we asked for the functional consequences of MALP-2 and IFN-γ by determining cellular influx into the lung. First, differential analysis of BAL cells was performed. Sensitization to OVA and inhalative OVA-challenge induced a highly significant influx of eosinophils into the BAL compared to the negative control. MALP-2 or IFN-γ alone raised the eosinophil counts even further. The number of BAL lymphocytes was also increased by both substances. In contrast thereto, the combination of both substances was able to abolish the allergen-induced eosinophilic influx almost to the level of the negative control. This was associated with an increase of neutrophils and macrophages (
FIG. 8 ). No systemic effect in terms of changes of the composition of the blood leukocytes were detected. - As expected from the BAL cell counts, allergen sensitization and challenge induced a massive infiltration of mainly eosinophils in the peribronchial compartment 24 hours after the last allergen challenge (
FIG. 9B ). This was not seen in unsensitized controls (FIG. 9A ). The low influx of leukocytes in the latter group might be due to an unspecific stimulus during instillation, as completely untreated animals did not show any infiltrates. MALP-2 and IFN-γ stimulation 48 hours prior to the last allergen challenge switched the predominant cell type seen in the sham treated group: tissue eosinophilia is reduced, and the most abundant leukocytes are neutrophils, which are also located peribronchialy (FIG. 9C ). After a recovery phase of 7 days, no differences in the histology compared to sham treated animals could be found any more (FIG. 9D ). - MALP-2 and IFN-γ Improve the Lung Function of Airflow Obstructed Animals
- In order to analyze the effect of MALP-2 and IFN-γ treatment on lung physiology, airway hyperreactivity was determined. For this purpose, the decrease of the EF50 after inhalation of increasing concentrations of methacholine (Mch) was measured using head-out body plethysmography 72 h after treatment and 24 h after the last allergen challenge. The course of EF50 in response to Mch is shown in
FIG. 10 . Hence, the ED50 as the concentration of Mch needed to decrease the EF50 to 50% of baseline was calculated. As expected, mice sensitized against OVA needed significantly lower concentrations of Mch to reach ED50 compared to unsensitized animals (16.58±1.61 mg/ml Mch vs. 29.92±3.73 mg/ml Mch (p<0.05)), indicating airway hyperreactivity (AHR). While neither MALP-2 (20.13±1.36 mg/ml Mch) nor IFN-γ (17.67±3.05 mg/ml Mch) significantly altered the allergen induced changes in lung function, the combination of both showed an improved AHR with an ED50 of 24.01±3.51 mg/ml Mch (p<0.05 vs. OVA). - Discussion
- DC have the potential of inducing different responses in lymphocytes. Depending on DC treatment, lymphocytes get activated or anergic, polarized according to the Th1/2 model or become Th0. This potential is termed plasticity of DC (Huang et al. Science 2001; 294(5543):870-5). In this study, it was shown that only DerP1-pulsed, otherwise immature DC of house dust mite allergics induce an autologous Th2-response (↓ IFN-g, ↑ IL-4), but that equally treated DC of non-allergics have no effect on lymphocytes (→ IFN-g, → IL-4).
- MALP-2 stimulation is known to induce maturation of DC. It upregulates costimulatory cell surface molecules and induces IL-10 secretion, while IL-12p70, a cytokine pivotal for inducing Th1 responses, was not produced. When cocultured with lymphocytes, MALP-2 treatment of DC leads to an enhanced lymphocyte proliferation, but does not influence the Th-polarization compared to unstimulated control-DC (Weigt et al. Immunobiol. 207, 1-11 (2003).
- IFNg, in contrast, is described to reduce immunostimulatory capacity of DC by downregulating costimulatory molecules (Rongcun et al. Cytokine 1998 October; 10(10):747-55).
- Herein it is shown in a human in vitro allergy model that the synthetic TLR-2/6 agonist MALP-2, in combination with IFN-γ, shifts the Th2 skew towards Th1. This is characterized by the induction of IL-12p70 and an upregulation of costimulatory cell surface molecules on dendritic cells. Neither substances alone was effective. The study outlined in Example 2 used a well established murine model of allergic airway inflammation and AHR, with OVA as allergen, to examine whether our earlier in vitro findings could be extended to an in vivo scenario. As expected, sensitization to OVA and a subsequent OVA aerosol challenge induced AHR, associated with tissue and BAL eosinophilia, and an increase of the cytokines IL-4, IL-5 and IL-13 in the lung lavage. Intratracheal treatment with a combination of MALP-2 with IFN-γ improved lung function of sensitized and challenged mice, and resolved eosinophilia, as well as the Th2-skewed cytokine milieu. As a side effect, a transient influx of neutrophils was observed. This side effect may be beneficial, as is discussed below. Neither substance alone significantly affected AHR.
- It is often difficult, if not impossible, to extrapolate from in vitro to in vivo data. This may be due to static conditions in cell future containing defined cell populations and an unphysiological accumulation of cytokines versus a dynamic scenario in vivo, involving blood and lymph circulation with concomitant removal of local mediators, degradation of the stimulating molecules, invasion of infiltrating cells producing yet different mediators, and many other unforeseeable effects. It is therefore not trivial that our in vivo findings reflect and extend in essence those from the foregoing in vitro experiments.
- Because of the findings for the individual substances, the astonishing upregulation of costimulatory molecules, of lymphocyte proliferation and the induction of Th1-responses of DC pretreated with MALP-2 together with IFN-g was not deducable from the pattern induced by either one of the stimuli.
- The massive induction of IL-12 proved to be of high importance for the effects seen in lymphocytes when cocultivating with respectively treated DC: the transfer of the allergen-dependent Th2 response to Th1 was reducible by blocking this cytokine with appropriate antibodies.
- In conclusion the use of MALP-2 and IFN-γ may prove an attractive alternative adjuvant for the treatment of e.g. allergic disease. As a next step, the safety and efficacy of this regime will be evaluated in a chronic model of asthma.
TABLE 1 CD 14CD 83CD 80CD 86PBS 18.4 +/− 9.7 55.6 +/− 8.3 44.4 +/− 17.9 173.1 +/− 29.1 DerP1 17.6 +/− 9.8 47.3 +/− 9 47.2 +/− 18.9 159.8 +/− 29.3 DerP1 + MALP-2 32.2 +/− 12.6 72.4 +/− 8.8 103.7 +/− 31.2 260.2 +/− 53.8 DerP1 + IFN-□ 16.4 +/− 10.1 38.6 +/− 6.2 69.3 +/− 17.2 123.9 +/− 25.7 DerP1 + MALP- 17 +/− 6.8 90.7 +/− 14.6 248.5 +/− 94.3 358.9 +/− 63.7 2 + IFN-□ CD 40HLA-DR CD1a PBS 670.6 +/− 153.6 390.9 +/− 109.9 207.6 +/− 68.1 DerP1 733 +/− 160.5 426.9 +/− 131.9 265.2 +/− 106.8 DerP1 + MALP-2 1389.6 +/− 269.9 746.1 +/− 295 291.2 +/− 109.3 DerP1 + IFN-□ 1769.4 +/− 519.9 669.1 +/− 204.2 199 +/− 69 DerP1 + MALP- 2673.9 +/− 717.5 1253.8 +/− 417.6 199.9 +/− 69.9 2 + IFN-□ -
TABLE 2 IL-4 IFN-□ PBS 9 +/− 5.8 8.7 +/− 3.8 DerP1 13.6 +/− 7.3 3.6 +/− 2.1 DerP1 + MALP-2 9.6 +/− 6.4 5.7 +/− 3.9 DerP1 + IFN-□ 11.8 +/− 7 29.6 +/− 9.3 DerP1 + MALP- 17.1 +/− 8.6 505.5 +/− 176.7 2 + IFN-□ -
TABLE 3 Description of the experimental groups. NaCl/ OVA/ OVA/ OVA/ OVA/ groups NaCl NaCl MALP-2 IFN-γ MALP-2 + IFN-γ sensitization/booster NaCl OVA OVA OVA OVA challenge OVA OVA OVA OVA OVA treatment (i.t.) NaCl NaCl 20 ng MALP-2 104 U IFN- γ 20 ng MALP-2 104 U IFN-γ animal number (n) 8 16 8 8 16
Claims (24)
1. Method for the preparation of a composition containing dendritic cells and/or lymphocytes, comprising the step of culturing dendritic cells (DC) from any source in the presence of at least one IFNγ receptor agonist and of at least one toll like receptor (TLR) 2 and/or TLR 6 agonist.
2. The method of claim 1 , wherein the source of DC includes progenitor derived DC, in particular monocyte derived DC and stem cell derived DC, or in vivo existent DC, in particular blood derived DC, and wherein the DC are preferably derived from autologous monocytes of a person or animal to be treated with said composition.
3. The method of claim 1 , wherein the IFNγ receptor agonist is the appropriate species-specific interferon gamma or a variant thereof.
4. The method according to claim 1 , wherein the TLR 2/6 agonist is a bisacyloxypropyl-5-cystein derivative, in particular a lipopeptide derived from Mycoplasma fermentans or a corresponding synthetic lipopeptide capable of stimulating macrophages in vitro or in vivo, preferably Macrophage Activating Lipopeptide 2 kDa (MALP-2) or biologically active derivatives thereof, in particular S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-rboxy-polyethylenglykol oder S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinyl-carboxy-polyethylenglykol.
5. The method according to claim 1 , wherein the treated DC are finally washed and preferably resuspended in water, saline or physiological medium.
6. The method according to claim 1 , wherein the DC are loaded with antigens.
7. The method according to claim 1 , wherein autologous or allogeneic lymphocytes acquired from the peripheral blood of donors are added, whereafter the DC and the lymphocytes and optionally further ingredients are cocultivated for a time period of up to several days, preferably at least 24 hours, more preferred at least 3 days.
8. The method according to claim 7 , wherein the lymphocytes are separated from the culture and optionally washed.
9. The method according to claim 1 , further comprising the step of processing the composition obtained into a therapeutical composition.
10. A therapeutical composition containing DC and/or lymphocytes cocultivated with said DC, said DC have acquired the property to drive a T helper cell type I response, obtainable by a method according to claim 1 .
11. A use of the therapeutical composition according to claim 10 as a vaccine for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.
12. The use of DC treated in vitro with at least one IFNγ receptor agonist in combination with at least one TLR 2 and/or TLR 6 agonist for the manufacture of a therapeutical composition for medical use, especially for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.
13. The use of lymphocytes cocultivated with DC treated with at least one IFNγ receptor agonist in combination with at least one TLR 2 and/or TLR 6 agonist for the manufacture of a therapeutical composition for medical use, especially for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.
14. The use according to claim 12 , where the DC have been treated with a method according to claim 1 .
15. A diagnostic method to monitor the immune status of persons or animals characterized in that DC which have been prestimulated with at least one IFNγ receptor agonist and at least one TLR 2 and/or TLR 6 agonist are cocultivated with autologous or allogenic lymphocytes, whereafter proliferation, release of molecules, cytotoxic activity and/or antibody formation are measured, and the data is evaluated.
16. Pharmaceutical composition comprising effective amounts of at least one IFNγ receptor agonist and at least one TLR 2 and/or TLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent.
17. A Pharmaceutical composition according to claim 16 wherein the IFNγ receptor agonist is the appropriate species-specific interferon gamma or a variant thereof.
18. A pharmaceutical composition according to claim 16 , wherein the TLR 2/6 agonist is a bisacyloxypropyl-S-cystein derivative, in particular a lipopeptide derived from Mycoplasma fermentans or a corresponding synthetic lipopeptide capable of stimulating macrophages in vitro or in vivo, preferably Macrophage Activating Lipopeptide 2 kDa (MALP-2) or biologically active derivatives thereof, in particular S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-rboxy-polyethylenglykol oder S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinyl-carboxy-polyethylenglykol.
19. A method for treating a subject by immunotherapy comprising the step of administering an effective amount of a therapeutical composition according to claim 10 to the subject in need thereof.
20. A method according to claim 19 for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.
21. A method according to claim 19 , wherein the dendritic cells and the lymphocytes are administered simultaneously, separately or sequentially.
22. A method according to claim 19 , wherein the at least one IFNγ receptor agonist and the at least one TLR 2 and/or TLR 6 agonist are administered simultaneously, separately or sequentially.
23. A method according to claim 16 , wherein the way of administering the composition is selected from the group consisting of oral, intradermal, subcutaneous, intravenously, inhalatively, intranasal, intranodal or by injection into or near the tumor in the case of cancer.
24. A method for treating a subject by immunotherapy comprising the step of administering an effective amount of a therapeutical composition according to claim 16 to the subject in need thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03012692A EP1484064A1 (en) | 2003-06-04 | 2003-06-04 | Therapeutical composition containing dentritic cells and use thereof |
EP03012692.4 | 2003-06-04 | ||
PCT/EP2004/005996 WO2004108145A1 (en) | 2003-06-04 | 2004-06-03 | Therapeutical composition containing dentritic cells and use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/005996 A-371-Of-International WO2004108145A1 (en) | 2003-06-04 | 2004-06-03 | Therapeutical composition containing dentritic cells and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/875,393 Continuation US8415152B2 (en) | 2003-06-04 | 2010-09-03 | Therapeutical composition containing dentritic cells and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070203185A1 true US20070203185A1 (en) | 2007-08-30 |
Family
ID=33155152
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/559,375 Abandoned US20070203185A1 (en) | 2003-06-04 | 2004-06-03 | Therapeutical Composition Containing Dentritic Cells And Use Thereof |
US12/875,393 Expired - Fee Related US8415152B2 (en) | 2003-06-04 | 2010-09-03 | Therapeutical composition containing dentritic cells and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/875,393 Expired - Fee Related US8415152B2 (en) | 2003-06-04 | 2010-09-03 | Therapeutical composition containing dentritic cells and use thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US20070203185A1 (en) |
EP (2) | EP1484064A1 (en) |
AT (1) | ATE460170T1 (en) |
CA (1) | CA2524910A1 (en) |
DE (1) | DE602004025936D1 (en) |
WO (1) | WO2004108145A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220265A1 (en) * | 1996-12-17 | 2003-11-27 | Muehlradt Peter F. | Dihydroxypropyl cysteine peptide and agent containing this peptide |
US11633458B2 (en) * | 2013-11-08 | 2023-04-25 | University Of Virginia Patent Foundation | Compositions and methods for treating melanoma |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007122392A1 (en) * | 2006-04-20 | 2007-11-01 | King's College London | Composition comprising a cytotoxic t-cell - inducing adjuvant |
DE102009034779A1 (en) | 2009-07-25 | 2011-02-03 | Emc Microcollections Gmbh | Synthetic analogues of bacterial lipopeptides and their application for the therapy and prophylaxis of allergic diseases |
DE102011018499A1 (en) | 2011-04-23 | 2012-10-25 | Emc Microcollections Gmbh | Topical nanoparticle vaccine for the immune stimulation of dendritic cells in the skin |
CA2991212A1 (en) | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
WO2017053873A1 (en) | 2015-09-26 | 2017-03-30 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for producing dendritic cells |
WO2018093907A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
FR2796961B1 (en) * | 1999-07-29 | 2003-05-02 | Chu Montpellier | PROCESS FOR OBTAINING DENTRITIC CELLS, DENTRITIC CELLS THUS OBTAINED AND THEIR USES FOR CLINICAL PURPOSES |
EP1291414A1 (en) * | 2001-09-11 | 2003-03-12 | Genethor GmbH | Ex vivo selection of T-cells with reduced alloreactivtiy (diminshed graft-versus-host effect and enhanced graft-verus-leukemia effect) and use therof in bone marrow transplantations |
ES2766299T3 (en) | 2001-09-06 | 2020-06-12 | Northwest Biotherapeutics Inc | Compositions and procedures for lymphocyte activation of monocytic dendritic cells and T cells to generate a Th-1 response |
EP1382352A1 (en) * | 2002-07-19 | 2004-01-21 | GBF Gesellschaft für Biotechnologische Forschung mbH | Bisacyloxypropylcystein conjugates and the use thereof |
-
2003
- 2003-06-04 EP EP03012692A patent/EP1484064A1/en not_active Withdrawn
-
2004
- 2004-06-03 EP EP04739563A patent/EP1641474B1/en not_active Expired - Lifetime
- 2004-06-03 DE DE602004025936T patent/DE602004025936D1/en not_active Expired - Lifetime
- 2004-06-03 WO PCT/EP2004/005996 patent/WO2004108145A1/en active Application Filing
- 2004-06-03 AT AT04739563T patent/ATE460170T1/en not_active IP Right Cessation
- 2004-06-03 US US10/559,375 patent/US20070203185A1/en not_active Abandoned
- 2004-06-03 CA CA002524910A patent/CA2524910A1/en not_active Abandoned
-
2010
- 2010-09-03 US US12/875,393 patent/US8415152B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220265A1 (en) * | 1996-12-17 | 2003-11-27 | Muehlradt Peter F. | Dihydroxypropyl cysteine peptide and agent containing this peptide |
US7435790B2 (en) * | 1996-12-17 | 2008-10-14 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Dihydroxypropyl cysteine peptide and agent containing this peptide |
US11633458B2 (en) * | 2013-11-08 | 2023-04-25 | University Of Virginia Patent Foundation | Compositions and methods for treating melanoma |
Also Published As
Publication number | Publication date |
---|---|
CA2524910A1 (en) | 2004-12-16 |
EP1641474A1 (en) | 2006-04-05 |
US20110070250A1 (en) | 2011-03-24 |
ATE460170T1 (en) | 2010-03-15 |
EP1641474B1 (en) | 2010-03-10 |
EP1484064A1 (en) | 2004-12-08 |
WO2004108145A1 (en) | 2004-12-16 |
US8415152B2 (en) | 2013-04-09 |
DE602004025936D1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8415152B2 (en) | Therapeutical composition containing dentritic cells and use thereof | |
EP1311658B1 (en) | Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells | |
Liau et al. | Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens | |
US7553661B2 (en) | Stromal antigen-presenting cells and use thereof | |
US20090297541A1 (en) | Maturation of dendritic cells | |
Giermasz et al. | Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines | |
CA2322712A1 (en) | Method for activating natural killer (nk) cells | |
Itoh et al. | Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells | |
CA2649290C (en) | Allogeneic cell therapy for treatment of opportunistic infection | |
US20050042751A1 (en) | Generation and use of new types of dendritic cells | |
US8282964B2 (en) | Ex-vivo treatment of peripheral plasmacytoid dendritic cells with IFN-lambda | |
WO2012158556A1 (en) | Tolerogenic plasmacytoid dendritic cells co-expressing cd8-alpha and cd8-beta and methods of inducing the differentiation of regulatory t cells using same | |
JP2004520033A (en) | Auxiliary composition for preparing differentiation-restricted mature dendritic cells | |
AT412145B (en) | METHOD FOR PRODUCING A CELLULAR IMMUNOTHERAPEUTICUM BASED ON IL-12 RELEASING DENDRITIC CELLS | |
US20240076616A1 (en) | Method for t-cell expansion and related medical applications | |
US20040241147A1 (en) | New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions | |
DE60130206T2 (en) | COMPOSITIONS AND METHODS OF PREPARING ANTIGEN-PRESENTING CELLS | |
ES2301494T3 (en) | DENDRITIC CELLS ACTIVATED IN THE PRESENCE OF GLUCOCORTICOID HORMONES ABLE TO DELETE THE RESPONSES OF CELLS SPECIFIC TO AN ANTIGEN. | |
Koh et al. | Effects of cytokine milieu secreted by BCG-treated dendritic cells on allergen-specific Th immune response | |
DK2847321T3 (en) | PROCEDURE FOR IN-VITRO MATURING DENDRIT CELLS | |
EP1871872B1 (en) | Method for activating cd8 t cells | |
Motiee et al. | The Effect of Antigen Dose and Antigen Presenting Process on T Cell Stimulation: A Method for Enrichment of TB10. 4 Antigen-specific T-cell Clones | |
FR2775692A1 (en) | Activating natural killer cells by treatment with dendritic cells or their products, for increasing the immune response in e.g. cancer and infections | |
CN117441678A (en) | Method for adoptively transferring pemphigus vulgaris animal model | |
US20040132185A1 (en) | Cd8alphadendritic cell differentiated from human hematopoietic stem cell and a method for differentiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HELMHOLTZ ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH, GE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUHLRADT, PETER F.;BRAUN, ARMIN;KRUG, NORBERT;AND OTHERS;REEL/FRAME:019155/0558;SIGNING DATES FROM 20070318 TO 20070323 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |